ArticleThe oncologist2026
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT-cell redirecting therapies, including T-cell engagers (TCEs) and Chimeric Antigen Receptor T-cell (CAR-T), are under investigation in metastatic castration-resistant prostate cancer (mCRPC). Despite their promising therapeutic potential, these therapies remain in early stages of development due to treatment-related adverse events (TRAEs). This study aims to quantify the frequency and severity of adverse events in clinical trials with a pooled analysis. MATERIALS AND
methodsA systematic search of PubMed, CINHAL, Scopus, and Ovid was conducted to identify clinical trials evaluating TCEs or CAR-T in patients with mCRPC. Types and frequencies of TRAEs were collected and analyzed using a random-effects model.
resultsThirteen TCEs trials involving 861 patients and 5 CAR-T trials involving 55 patients were identified. Cytokine release syndrome occurred in 59% (95% confidence interval: 25, 86) and 43% (28, 59) with TCEs and CAR-T, respectively. Neurologic TRAEs occurred in 39% (22, 60) with CAR-T compared to 9% (4, 17) with TCEs (P < 0.0001). Hematologic and hepatic TRAEs occurred in 34% (8, 75) and 25% (12, 44) with CAR-T, compared to 23% (7, 56) and 33% (12, 64) with TCEs, respectively. Musculoskeletal/dermatologic TRAEs occurred in 33% (24, 42) and 29% (8, 58) with TCEs and CAR-T, respectively. Renal and gastrointestinal TRAEs occurred in 21% (5, 51) and 14% (2, 43) with CAR-T, compared to 15% (8, 25) and 21% (12, 36) with TCEs, respectively.
conclusionsThese data underscore the TRAE profiles associated with these therapies and emphasize the importance of differentiating off-target toxicities from immune effector cell-toxicities to inform the development of effective TRAE mitigation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.